Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

2IMvigor-211 (PDL1>5%), 2018 IMvigor-211 (PDL1>1%), 20181KEYNOTE-045 (PDL1 CPS >10%), 2017atezolizumab alone vs. pembrolizumab alone 1.53 [0.96; 2.43]1.53 [0.96;2.43]atezolizumab alone vs. pembrolizumab alone 1.53 [0.96; 2.43]atezolizumab alone vs. Standard of Care (SoC) 0.87 [0.74; 1.03]0.87 [0.74;1.03]atezolizumab alone vs. Standard of Care (SoC) 0.87 [0.74; 1.03]pembrolizumab alone vs. atezolizumab alone 0.66 [0.41; 1.04]0.66 [0.41;1.04]pembrolizumab alone vs. atezolizumab alone 0.66 [0.41; 1.04]pembrolizumab alone vs. Standard of Care (SoC) pembrolizumab alone better 0.57 [0.37; 0.88]0.57 [0.37;0.88]pembrolizumab alone vs. Standard of Care (SoC) pembrolizumab alone better 0.57 [0.37; 0.88]Standard of Care (SoC) vs. atezolizumab alone 1.15 [0.97; 1.36]1.15 [0.97;1.36]Standard of Care (SoC) vs. atezolizumab alone 1.15 [0.97; 1.36]Standard of Care (SoC) vs. pembrolizumab alone pembrolizumab alone better 1.75 [1.14; 2.71]1.75 [1.14;2.71]Standard of Care (SoC) vs. pembrolizumab alone pembrolizumab alone better 1.75 [1.14; 2.71]Standard of Care (SoC)atezolizumab alonepembrolizumab alonedirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)atezolizumab alonepembrolizumab alone
Standard of Care (SoC)---1.15
0.97; 1.36		1.75
1.14; 2.71
atezolizumab alone0.87
0.74; 1.03		---1.53
0.96; 2.43
pembrolizumab alone0.57
0.37; 0.88		0.66
0.41; 1.04		---

pathologies: 154 - treatments: 359,575,577,576,869 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons